Connection
Kevin Ginn to Nifurtimox
This is a "connection" page, showing publications Kevin Ginn has written about Nifurtimox.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.057 |
|
|
|
-
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL. A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma. Int J Cancer. 2023 Sep 01; 153(5):1026-1034.
Score: 0.057